1878-A INDIVIDUALIZED HCV TREATMENT FOR PWIDS ON OPIOID AGONIST THERAPY LED TO EXCELLENT ADHERENCE THROUGHOUT THE COVID19 PANDEMIC Caroline Schwarz 1,2 , Angelika Schtz 3 , Raphael Schubert 3 , Michael Schwarz 2 , Anika Jenke 3 , David Josef Maria Bauer 1,2 , Lukas Burghart 1,2 , Benjamin Steinwender 3 , Enisa Gutic 1 , Thomas Reiberger 2,4 , Hans Haltmayer 3 and Michael Gschwantler 1,5 , (1)Klinik Ottakring, (2)Medical University of Vienna, (3)Suchthilfe Wien Ggmbh, (4)Cemm Research Center for Molecular Medicine of the Austrian Academy of Sciences, (5)Sigmund Freud University Background: Directly observed therapy (DOT) with DAAs (direct-acting antivirals) is successful in eliminating HCV in PWIDs (people who inject drugs) on opioid agonist therapy (OAT): DAAs are prescribed via a low-threshold facility (LTF), and supervised DAA administration alongside OAT is performed at a pharmacy or LTF
Its ideal for individuals with low iron, chronic fatigue, or increased iron needs who want faster, more reliable replenishment than oral supplements
Hair peptides deliver a personalised protocol tailored to your unique needs, combining professional guidance, medical supervision, and ongoing progress tracking
Bohnen NI, Kaufer DI, Hendrickson R, Constantine GM, Mathis CA, Moore RY
Thus, for patients who are unresponsive to symptomatic treatments, some experts suggest considering a dosage of 250 mg of acetazolamide twice daily
doi: 10.1164/rccm.200612-1804OC 109 UsherLRLawsonRAGearyITaylorCJBingleCDTaylorGWet al
